ZIMLAB Zim Laboratories Q4 FY25 results (Jan–Mar 2025) and concall
Zim Laboratories reported a mixed Q4 FY25 with strong sequential growth but a YoY decline in revenue and PAT. Full-year FY25 saw modest revenue and EBITDA growth, with margins improving to 13.1%. The company emphasized its strategic pivot towards New Innovative Products (NIP) and Oral Thin Films (OTF), which contributed 16.5% to FY25 revenue, and expressed confidence in future growth and margin expansion driven by these segments and new market entries, despite current geopolitical and regulatory uncertainties.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 90 | 95 | 109 |
| EBITDA | 8 | 12 | 15 |
| Net profit | 1 | 4 | 5 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
